Bone Age Maturation and Growth Outcomes in Young Children with CAH Treated with Hydrocortisone Suspension.
Heba Al-RayessO Yaw AddoElise PalzerMu'taz JaberKristin FleissnerJames HodgesRichard BrundageBradley S MillerKyriakie SarafoglouPublished in: Journal of the Endocrine Society (2021)
-scores, allowed lower average and cumulative daily HC dose compared to HC tablets, and generated no significant differences in SDS in growth parameters in children with CAH at 4 years of age. Longitudinal studies of treating with smaller HC doses during childhood are needed.